Charles Schwab Investment Management Inc Tyme Technologies, Inc. Transaction History

Charles Schwab Investment Management Inc

$519 Billion
Q2 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$0.23 - $0.35 $24,514 - $37,304	106,584 New	106,584 $30,000
Q1 2022 May 13, 2022	SELL	$0.28 - $0.68 $12,039 - $29,238	-42,998 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.14 - $1.87 $175,342 - $287,622	-153,809 Reduced 78.15%	42,998 $55,000
Q1 2021 May 17, 2021	BUY	$1.34 - $3.53 $46,163 - $121,608	34,450 Added 21.22%	196,807 $351,000
Q2 2020 Aug 14, 2020	BUY	$0.97 - $1.7 $17,454 - $30,589	17,994 Added 12.46%	162,357 $216,000
Q2 2019 Aug 09, 2019	SELL	$0.96 - $1.89 $74,397 - $146,469	-77,497 Reduced 34.93%	144,363 $177,000
Q4 2018 Feb 14, 2019	BUY	$2.01 - $4.21 $288,354 - $603,966	143,460 Added 182.98%	221,860 $819,000
Q2 2018 Aug 08, 2018	BUY	$2.05 - $4.09 $160,720 - $320,656	78,400 New	78,400 $248,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.